<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Revised (2018) Vaughan Williams classification of antiarrhythmic drugs</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Revised (2018) Vaughan Williams classification of antiarrhythmic drugs</h1>
<div class="graphic"><div class="figure"><div class="ttl">Revised (2018) Vaughan Williams classification of antiarrhythmic drugs</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="7%"></colgroup><colgroup span="5" width="14%"></colgroup> <tbody> <tr> <td class="subtitle1">Class</td> <td class="subtitle1">Subclass</td> <td class="subtitle1">Pharmacological targets</td> <td class="subtitle1">Electrophysiological effects</td> <td class="subtitle1">Examples of drugs</td> <td class="subtitle1">Major clinical applications</td> <td class="subtitle1">Corresponding likely therapeutic mechanism(s)</td> </tr> <tr> <td class="subtitle2_left" colspan="7">HCN channel blockers</td> </tr> <tr class="divider_bottom"> <td class="indent1">0</td> <td class="centered"> </td> <td>HCN channel-mediated pacemaker current (I<sub>f</sub>) block</td> <td>Inhibition of I<sub>f</sub> reducing SAN phase 4 pacemaker depolarization rate, thereby reducing heart rate; possible decreased AVN and Purkinje cell automaticity; increase in RR intervals</td> <td>Ivabradine</td> <td> <ul> <li>Stable angina and chronic heart failure with heart rate ≥70 beats per minute </li> <li>Potential new applications for tachyarrhythmias </li> </ul> </td> <td> <ul> <li>Reduction in SAN automaticity </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="7">Voltage-gated Na<sup>+</sup> channel blockers</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="4">I</td> <td class="centered">Ia</td> <td>Nav1.5 open state; intermediate (Tau ≈ 1 to 10 seconds) dissociation kinetics; often concomitant K<sup>+</sup> channel block</td> <td>Reduction in peak I<sub>Na</sub>, AP generation, and (dV/dt)<sub>max</sub> with increased excitation threshold; slowing of AP conduction in atria, ventricles, and specialized ventricular conduction pathways; concomitant I<sub>K</sub> block increasing APD and ERP; increase in QT intervals</td> <td>Quinidine, ajmaline, disopyramide</td> <td> <ul> <li>Supraventricular tachyarrhythmias, particularly recurrent atrial fibrillation; ventricular tachycardia, ventricular fibrillation (including SQTS and Brugada syndrome) </li> </ul> </td> <td> <ul> <li>Reduction in ectopic ventricular/atrial automaticity </li> <li>Reduction in accessory pathway conduction </li> <li>Increase in refractory period, decreasing reentrant tendency </li> </ul> </td> </tr> <tr> <td class="centered">Ib</td> <td>Nav1.5 open state; rapid dissociation (Tau ≈ 0.1 to 1 second); I<sub>Na</sub>; window current</td> <td> <p>Reduction in peak I<sub>Na</sub>, AP generation and (dV/dt)<sub>max</sub> with increased excitation threshold; slowing of AP conduction in atria, ventricles, and specialized ventricular conduction pathways; shortening of APD and ERP in normal ventricular and Purkinje myocytes; prolongation of ERP and postrepolarization refractoriness with reduced window current in ischemic, partially depolarized cells</p> Relatively little electrocardiographic effect; slight QTc shortening</td> <td>Lidocaine, mexiletine</td> <td> <ul> <li>Ventricular tachyarrhythmias (ventricular tachycardia, ventricular fibrillation), particularly after myocardial infarction </li> </ul> </td> <td> <ul> <li>Reduction in ectopic ventricular automaticity </li> <li>Reduction in DAD-induced triggered activity </li> <li>Reduced reentrant tendency by converting unidirectional to bidirectional block, particularly in ischemic, partially depolarized myocardium </li> </ul> </td> </tr> <tr> <td class="centered">Ic</td> <td>Nav1.5 inactivated state; slow dissociation (Tau &gt;10 seconds)</td> <td>Reduction in peak I<sub>Na</sub>, AP generation and (dV/dt)<sub>max</sub> with increased excitation threshold; slowing of AP conduction in atria, ventricles, and specialized ventricular conduction pathways; reduced overall excitability; prolongation of APD at high heart rates; increase in QRS duration</td> <td>Propafenone, flecainide</td> <td> <ul> <li>Supraventricular tachyarrhythmias (atrial tachycardia, atrial flutter, atrial fibrillation, and tachycardias involving accessory pathways) </li> <li>Ventricular tachyarrhythmias resistant to other treatment in the absence of structural heart disease, premature ventricular contraction, catecholaminergic polymorphic ventricular tachycardia </li> </ul> </td> <td> <ul> <li>Reduction in ectopic ventricular/atrial automaticity </li> <li>Reduction in DAD-induced triggered activity </li> <li>Reduced reentrant tendency by converting unidirectional to bidirectional block </li> <li>Slowed conduction and reduced of excitability particularly at rapid heart rates blocking reentrant pathways showing depressed conduction </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="centered">Id</td> <td>Nav1.5 late current</td> <td>Reduction in late Na<sup>+</sup> current (I<sub>NaL</sub>), affecting AP recovery, refractoriness, repolarization reserve, and QT interval</td> <td>Ranolazine</td> <td> <ul> <li>Stable angina, ventricular tachycardia </li> <li>As a potential new class of drugs for the management of tachyarrhythmias </li> </ul> </td> <td> <ul> <li>Decrease in AP recovery time </li> <li>Reduction in EAD-induced triggered activity </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="7">Autonomic inhibitors and activators</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="5">II</td> <td class="centered">IIa</td> <td>Nonselective beta- and selective beta1-adrenergic receptor inhibitors</td> <td>Inhibition of adrenergically induced G<sub>s</sub> protein-mediated effects of increased adenylyl kinase activity and [cAMP]<sub>i</sub> with effects including slowed SAN pacemaker rate caused by reduced I<sub>f</sub> and I<sub>CaL</sub>; increased AVN conduction time and refractoriness, and decreased SAN pacing and triggered activity resulting from reduced I<sub>CaL</sub>; and reduced RyR2-mediated SR Ca<sup>2+</sup> release and triggered activity; increase in RR and PR intervals</td> <td> <p>Nonselective beta inhibitors: carvedilol, propranolol, nadolol</p> Selective beta1-adrenergic receptor inhibitors: atenolol, bisoprolol, betaxolol, celiprolol, esmolol, metoprolol</td> <td> <ul> <li>Sinus tachycardia or other types of tachycardic, including supraventricular (atrial fibrillation, atrial flutter, atrial tachycardia), arrhythmias </li> <li>Rate control of atrial fibrillation and ventricular tachyarrhythmias (ventricular tachycardia, premature ventricular contraction) </li> <li>NOTE: atenolol, propranolol, and nadolol also used in LQTS; nadolol used in catecholaminergic polymorphic ventricular tachycardia </li> </ul> </td> <td> <ul> <li>Reduction in SAN automaticity </li> <li>Reduction in AVN automaticity </li> <li>Reduction in ectopic ventricular/atrial automaticity </li> <li>Reduction in EAD-/DAD-induced triggered activity </li> <li>Reduced SAN reentry </li> <li>Reduction in AVN conduction terminating reentry </li> </ul> </td> </tr> <tr> <td class="centered">IIb</td> <td>Nonselective beta-adrenergic receptor activators</td> <td>Activation of adrenergically induced G<sub>s</sub>-protein effects of increasing adenylyl kinase activity and [cAMP]<sub>i</sub> (refer to entry above); decrease in RR and PR intervals</td> <td>Isoproterenol</td> <td> <ul> <li>Accelerating rates of ventricular escape rhythm in cases of complete atrioventricular block before definitive pacemaker implantation </li> <li>Acquired, often drug-related bradycardia-dependent torsades de pointes </li> </ul> </td> <td> <ul> <li>Increased escape ventricular automaticity </li> <li>Suppression of bradycardia-dependent EAD-related triggered activity </li> </ul> </td> </tr> <tr> <td class="centered">IIc</td> <td>Muscarinic M<sub>2</sub> receptor inhibitors</td> <td>Inhibition of supraventricular (SAN, atrial, AVN) muscarinic M<sub>2</sub> cholinergic receptors (refer to entry below); decreased RR and PR intervals</td> <td>Atropine, anisodamine, hyoscine, scopolamine</td> <td> <ul> <li>Mild or moderate symptomatic sinus bradycardia </li> <li>Supra-His, AVN, conduction block, eg, in vagal syncope or acute inferior myocardial infarction </li> </ul> </td> <td> <ul> <li>Increase in SAN automaticity </li> <li>Increase in AVN conduction </li> </ul> </td> </tr> <tr> <td class="centered">IId</td> <td>Muscarinic M<sub>2</sub> receptor activators</td> <td>Activation of supraventricular (SAN, atrial, AVN) muscarinic M<sub>2</sub> cholinergic receptors activates K<sub>ACh</sub> channels, hyperpolarizing the SAN and shortening APDs in atrial and AVN tissue, and reduces [cAMP]<sub>i</sub> and therefore I<sub>CaL</sub> and SAN I<sub>f</sub>; inhibitory effects on adenylyl cyclase and cAMP activation, reducing its stimulatory effects on I<sub>CaL</sub>, I<sub>Ks</sub>, I<sub>Cl</sub>, and I<sub>ti</sub> in adrenergically activated ventricular tissue; increased RR and PR intervals</td> <td>Carbachol, pilocarpine, methacholine, digoxin</td> <td> <ul> <li>Sinus tachycardia or supraventricular tachyarrhythmias </li> </ul> </td> <td> <ul> <li>Reduction in SAN automaticity </li> <li>Reduced SAN reentry </li> <li>Reduction in AVN conduction, terminating reentry </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="centered">IIe</td> <td>Adenosine A<sub>1</sub> receptor activators</td> <td>Activation of adenosine A<sub>1</sub> receptors in supraventricular tissue (SAN, atrial, AVN) activates G protein-coupled inward rectifying K<sup>+</sup> channels and I<sub>KAdo</sub> current, hyperpolarizing the SAN and shortening APDs in atrial and AVN tissue, and reduces [cAMP]<sub>i</sub> and therefore I<sub>CaL</sub> and SAN I<sub>f</sub>; inhibitory effects on adenylyl cyclase and cAMP activation, reducing its stimulatory effects on I<sub>CaL</sub>, I<sub>Ks</sub>, I<sub>Cl</sub>, and I<sub>ti</sub> in adrenergically activated ventricular tissue; increased RR and increased PR intervals</td> <td>Adenosine, ATP; aminophylline acts as an adenosine receptor inhibitor</td> <td> <ul> <li>Acute termination of AVN tachycardia and cAMP-mediated triggered VTs </li> <li>Differentiation of sinus from atrial tachycardia </li> </ul> </td> <td> <ul> <li>Reduction in SAN automaticity </li> <li>Reduction in AVN conduction, terminating reentry </li> <li>Reduction in EAD-/DAD-induced triggered activity </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="7">K<sup>+</sup> channel blockers and openers</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="7">III</td> </tr> <tr> <td class="indent2">Voltage dependent K<sup>+</sup> channel blockers</td> <td class="centered">IIIa</td> <td>Nonselective K<sup>+</sup> channel blockers</td> <td>Block of multiple K<sup>+</sup> channel targets resulting in prolonged atrial, Purkinje, and/or ventricular myocyte AP recovery, increased ERP, and reduced repolarization reserve; prolonged QT intervals</td> <td>Ambasilide, amiodarone, dronedarone</td> <td> <ul> <li>Ventricular tachycardia in patients without structural heart disease or with remote myocardial infarction; tachyarrhythmias with Wolff-Parkinson-White syndrome </li> <li>Atrial fibrillation with atrioventricular conduction via accessory pathway </li> <li>Ventricular fibrillation and premature ventricular contraction </li> <li>Tachyarrhythmias associated with supraventricular arrhythmias and atrial fibrillation </li> </ul> </td> <td> <ul> <li>Increase in AP recovery time </li> <li>Increase in refractory period, with decreased reentrant tendency </li> <li>NOTE: amiodarone also slows sinus node rate and atrioventricular conduction </li> </ul> </td> </tr> <tr> <td class="indent2"> </td> <td class="centered"> </td> <td>Kv11.1 (HERG) channel-mediated rapid K<sup>+</sup> current (I<sub>Kr</sub>) blockers</td> <td>Prolonged atrial, Purkinje, and ventricular myocyte AP recovery, increased ERP, and reduced repolarization reserve; prolonged QT intervals</td> <td>Dofetilide, ibutilide, sotalol</td> <td> <ul> <li>Ventricular tachycardia in patients without structural heart disease or with remote myocardial infarction </li> <li>Tachyarrhythmias associated with Wolff-Parkinson-White syndrome </li> <li>Atrial fibrillation with atrioventricular conduction via accessory pathway, ventricular fibrillation, premature ventricular contraction </li> <li>Tachyarrhythmias associated with supraventricular arrhythmias and atrial fibrillation </li> </ul> </td> <td> <ul> <li>Increase in AP recovery time </li> <li>Increase in refractory period with decreased reentrant tendency </li> </ul> </td> </tr> <tr> <td class="indent2"> </td> <td class="centered"> </td> <td>Kv7.1 channel-mediated, slow K<sup>+</sup> current (I<sub>Ks</sub>) blockers</td> <td>Prolonged atrial, Purkinje, and ventricular myocyte AP recovery, increased ERP, and reduced repolarization reserve; prolonged QT intervals</td> <td>No clinically approved drugs in use</td> <td> </td> <td> <ul> <li>Increase in AP recovery time </li> <li>Increase in refractory period with decreased reentrant tendency </li> </ul> </td> </tr> <tr> <td class="indent2"> </td> <td class="centered"> </td> <td>Kv1.5 channel-mediated, ultrarapid K<sup>+</sup> current (I<sub>Kur</sub>) blockers</td> <td>Prolonged atrial AP recovery, increased ERP, and reduced repolarization reserve</td> <td>Vernakalant</td> <td> <ul> <li>Immediate conversion of atrial fibrillation </li> </ul> </td> <td> <ul> <li>Atrium-specific actions: increase in AP recovery time and increase in refractory period with decreased reentrant tendency </li> </ul> </td> </tr> <tr> <td class="indent2"> </td> <td class="centered"> </td> <td>Kv1.4 and Kv4.2 channel-mediated transient outward K<sup>+</sup> current (I<sub>to1</sub>) blockers</td> <td>Prolonged atrial, Purkinje, and ventricular myocyte AP recovery, increased ERP, and reduced repolarization reserve, particularly in subepicardial as opposed to subendocardial ventricular cardiomyocytes</td> <td>Blocker under regulatory review for the acute conversion of atrial fibrillation: tedisamil</td> <td> </td> <td> <ul> <li>Increase in AP recovery time; increase in refractory period, with decreased reentrant tendency </li> </ul> </td> </tr> <tr> <td class="indent2">Metabolically dependent K<sup>+</sup> channel openers</td> <td class="centered">IIIb</td> <td>Kir6.2 (I<sub>KATP</sub>) openers</td> <td>Opening of ATP-sensitive K<sup>+</sup> channels (I<sub>KATP</sub>), shortening AP recovery, refractoriness, and repolarization reserve in all cardiomyocytes apart from SAN cells; shortened QT intervals</td> <td>Nicorandil, pinacidil</td> <td> <ul> <li>Nicorandil: treatment of stable angina (second line); pinacidil: investigational drug for the treatment of hypertension </li> </ul> </td> <td> <ul> <li>Potential decrease in AP recovery time </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent2">Transmitter dependent K<sup>+</sup> channel blockers</td> <td class="centered">IIIc</td> <td>GIRK1 and GIRK4 (I<sub>KACh</sub>) blockers</td> <td>Inhibition of direct or G<sub>i</sub> protein βγ-subunit-mediated activation of I<sub>KACh</sub>, particularly in SAN, AVN, and atrial cells, prolonging APD and ERP and decreasing repolarization reserve</td> <td>Blocker under regulatory review for management of atrial fibrillation: BMS 914392</td> <td> </td> <td> <ul> <li>Reduction in SAN automaticity </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="7">Ca<sup>2+</sup> handling modulators</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="7">IV</td> </tr> <tr> <td class="indent2">Surface membrane Ca<sup>2+</sup> channel blockers</td> <td class="centered">IVa</td> <td>Nonselective surface membrane Ca<sup>2+</sup> channel blockers</td> <td>Block of Ca<sup>2+</sup> current (I<sub>Ca</sub>), resulting in inhibition of SAN pacing, inhibition of AVN conduction, prolonged ERP, increased AP recovery time, increased refractory period, diminished repolarization reserve, and suppression of intracellular Ca<sup>2+</sup> signaling; increased PR intervals</td> <td>Bepridil</td> <td> <ul> <li>Angina pectoris </li> <li>Potential management of supraventricular tachyarrhythmias </li> </ul> </td> <td> <ul> <li>Reduction in AVN conduction, terminating reentry </li> <li>Reduction in EAD-/DAD-induced triggered activity </li> </ul> </td> </tr> <tr> <td class="indent2"> </td> <td class="centered"> </td> <td>Ca<sub>v</sub>1.2 and Ca<sub>v</sub>1.3 channel mediated L-type Ca<sup>2+</sup> current (I<sub>CaL</sub>) blockers</td> <td>Block of Ca<sup>2+</sup> current (I<sub>Ca</sub>), resulting in inhibition of SAN pacing, inhibition of AVN conduction, prolonged ERP, increased AP recovery time, increased refractory period, diminished repolarization reserve, and suppression of intracellular Ca<sup>2+</sup> signaling; increased PR intervals</td> <td>Phenylalkylamines (eg, verapamil), benzothiazepines (eg, diltiazem)</td> <td> <ul> <li>Supraventricular arrhythmias and ventricular tachycardia without structural heart disease </li> <li>Rate control of atrial fibrillation </li> </ul> </td> <td> <ul> <li>Reduction in AVN conduction, terminating reentry </li> <li>Reduction in EAD-/DAD-induced triggered activity </li> </ul> </td> </tr> <tr> <td class="indent2"> </td> <td class="centered"> </td> <td>Ca<sub>v</sub>3.1 channel mediated T-type Ca<sup>2+</sup> current (I<sub>CaT</sub>) blockers</td> <td>Inhibition of SAN pacing, prolonged His-Purkinje phase 4 repolarization, absent from ventricular cells</td> <td>No clinically approved drugs in use</td> <td> </td> <td> </td> </tr> <tr> <td class="indent2">Intracellular Ca<sup>2+</sup> channel blockers</td> <td class="centered">IVb</td> <td>SR RyR2-Ca<sup>2+</sup> channel blockers</td> <td>Reduced SR Ca<sup>2+</sup> release: reduced cytosolic and SR [Ca<sup>2+</sup>]</td> <td>Flecainide, propafenone</td> <td> <ul> <li>Catecholaminergic polymorphic ventricular tachycardia </li> </ul> </td> <td> <ul> <li>Reduction in DAD-induced triggered activity </li> </ul> </td> </tr> <tr> <td class="indent2"> </td> <td class="centered"> </td> <td>IP<sub>3</sub>R-Ca<sup>2+</sup> channel blockers</td> <td>Reduced atrial SR Ca<sup>2+</sup> release; reduced cytosolic and SR [Ca<sup>2+</sup>]</td> <td>No clinically approved drugs in use</td> <td> </td> <td> </td> </tr> <tr> <td class="indent2">Sarcoplasmic reticular Ca<sup>2+</sup>-ATPase activators</td> <td class="centered">IVc</td> <td>Sarcoplasmic reticular Ca<sup>2+</sup> pump activators</td> <td>Increased Ca<sup>2+</sup>-ATPase activity, increased SR [Ca<sup>2+</sup>]</td> <td>No clinically approved drugs in use</td> <td> </td> <td> <ul> <li>Reduction in DAD-induced triggered activity </li> </ul> </td> </tr> <tr> <td class="indent2">Surface membrane ion exchange inhibitors</td> <td class="centered">IVd</td> <td>Surface membrane ion exchanger (eg, SLC8A) inhibitors</td> <td>Reduced Na<sup>+</sup>–Ca<sup>2+</sup> exchange reduces depolarization associated with rises in subsarcolemmal [Ca<sup>2+</sup>]</td> <td>No clinically approved drugs in use</td> <td> </td> <td> <ul> <li>Reduction in EAD-/DAD-induced triggered activity </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent2">Phosphokinase and phosphorylase inhibitors</td> <td class="centered">IVe</td> <td>Increased/decreased phosphorylation levels of cytosolic Ca<sup>2+</sup> handling proteins</td> <td>Includes CaMKII modulators: altered intracellular Ca<sup>2+</sup> signaling</td> <td>No clinically approved drugs in use</td> <td> </td> <td> <ul> <li>Reduction in EAD-/DAD-induced triggered activity </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="7">Mechanosensitive channel blockers</td> </tr> <tr class="divider_bottom"> <td class="indent1">V</td> <td class="centered"> </td> <td>Transient receptor potential channel (TRPC3/TRPC6) blockers</td> <td>Intracellular Ca<sup>2+</sup> signaling</td> <td>Blocker under investigation: N–(p-amylcinnamoyl) anthranilic acid</td> <td> </td> <td> <ul> <li>Reduction in EAD-/DAD-induced triggered activity </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="7">Gap junction channel blockers</td> </tr> <tr class="divider_bottom"> <td class="indent1">VI</td> <td class="centered"> </td> <td>Cx (Cx40, Cx43, Cx45) blockers</td> <td>Reduced cell-cell coupling and AP propagation; Cx40: atria, AVN, ventricular conduction system; Cx43: atria and ventricles, distal conduction system; Cx45: SAN, AVN, conducting bundles</td> <td>Blocker under investigation: carbenoxolone</td> <td> </td> <td> <ul> <li>Reduction in ventricular/atrial conduction </li> <li>Reduction in accessory pathway conduction </li> <li>Reduction in AVN conduction </li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="7">Upstream target modulators</td> </tr> <tr> <td class="indent1" rowspan="4">VII</td> <td class="centered"> </td> <td>Angiotensin-converting enzyme inhibitors</td> <td>Electrophysiological and structural (fibrotic, hypertrophic, or inflammatory) remodeling</td> <td>Captopril, enalapril, delapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, cilazapril</td> <td> <ul> <li>Management of hypertension, symptomatic heart failure </li> <li>Potential application reducing arrhythmic substrate </li> </ul> </td> <td> <ul> <li>Reduction of structural and electrophysiological remodeling changes that compromise AP conduction and increase reentrant tendency </li> </ul> </td> </tr> <tr> <td class="centered"> </td> <td>Angiotensin receptor blockers</td> <td>Electrophysiological and structural (fibrotic, hypertrophic, or inflammatory) remodeling</td> <td>Losartan, candesartan, eprosartan, telmisartan, irbesartan, olmesartan, valsartan, saprisartan</td> <td> <ul> <li>Management of hypertension, symptomatic heart failure </li> <li>Potential application reducing arrhythmic substrate </li> </ul> </td> <td> <ul> <li>Reduction of structural and electrophysiological remodeling changes that compromise AP conduction and increase reentrant tendency </li> </ul> </td> </tr> <tr> <td class="centered"> </td> <td>Omega-3 fatty acids</td> <td>Electrophysiological and structural (fibrotic, hypertrophic, or inflammatory) remodeling</td> <td>Omega-3 fatty acids: eicosapentaenoic acid, docosahexaenoic acid, docosapentaenoic acid</td> <td> <ul> <li>Post-myocardial infarct reduction of risk of cardiac death, myocardial infarct, stroke, and abnormal cardiac rhythms </li> </ul> </td> <td> <ul> <li>Reduction of structural and electrophysiological remodeling changes that compromise AP conduction and increase reentrant tendency </li> </ul> </td> </tr> <tr> <td class="centered"> </td> <td>Statins</td> <td>Electrophysiological and structural (fibrotic, hypertrophic, or inflammatory) remodeling</td> <td>Statins</td> <td> <ul> <li>Post-myocardial infarct reduction of risk of cardiac death, myocardial infarct, stroke, and abnormal cardiac rhythms </li> </ul> </td> <td> <ul> <li>Reduction of structural and electrophysiological remodeling changes that compromise AP conduction and increase reentrant tendency </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">HCN: hyperpolarization-activated cyclic nucleotide-gated; SAN: sino-atrial node; AVN: atrioventricular node; AP: action potential; APD: action potential duration; ERP: effective refractory period; SQTS: short-QT syndrome; DAD: delayed afterdepolarization; EAD: early afterdepolarization; RyR2: ryanodine receptor 2; SR: sarcoplasmic reticulum; CaMKII: calcium/calmodulin kinase II.</div><div class="graphic_reference">From: Lei M, Wu L, Terrar DA, et al. Modernized classification of cardiac antiarrhythmic drugs. Circulation 2018; 138:1879. Available at: <a href="https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.118.035455" target="_blank">https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.118.035455</a> (Accessed on January 29, 2019). Reproduced under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License</a>.</div><div id="graphicVersion">Graphic 120226 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
